Celsion Presents Data on ThermoDox® plus Optimized RFA in Intermediate HCC at the 2nd Asian Conference on Tumor Ablation (ACTA)

On November 2, 2015 Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, reported the presentation of data from the Company’s HEAT Study, highlighting the curative potential for ThermoDox plus optimized radiofrequency ablation (RFA) in intermediate primary liver cancer, also known as hepatocellular carcinoma (HCC), as well as preclinical data on the correlation of heating duration during RFA in combination with ThermoDox (Press release, Celsion, NOV 2, 2015, View Source [SID:1234507870]). The clinical data were presented by two leading liver cancer experts from South Korea and Taiwan, Professor Won Young Tak, MD, Ph.D., Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea and Dr. Shi-Ming Lin, MD, co-chair ACTA 2015 and vice chairman, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Taipei, Taiwan, on October 30-31, 2015 at the 2015 Asian Conference on Tumor Ablation (ACTA) in Fukuoka, Japan.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"There is clear evidence that the duration of the RFA regimen is critical when treating patients with ThermoDox," said Professor Tak, lead investigator in South Korea for the Company’s HEAT and OPTIMA studies. "Findings from the data presented at ACTA, including the multivariate analysis, HEAT Study data demonstrating compelling survival outcomes and supportive preclinical data, underscore the importance of Celsion’s ongoing OPTIMA Study, which is designed to demonstrate the potential of ThermoDox with an optimized RFA regimen in this setting."

"The incidence rate of HCC within Asian countries is growing at an alarming rate, with current estimates projecting that Asia will account for approximately 75% of newly diagnosed cases annually," said Professor Lin, lead investigator in Taiwan for the Company’s HEAT and OPTIMA studies. "The totality of the data presented demonstrate that ThermoDox plus optimized RFA has a strong potential to serve as a curative therapy for patients with liver cancer, where there exists a strong unmet need for effective treatment options."

The three presentations included:

"Effect of Radiofrequency Ablation (RFA) Dwell Time (+/-) ThermoDox on Safety and Overall Survival (OS) Among 452 Intermediate Solitary HCC Patients With Lesions 3 to 7 cm: HEAT Study Data," by Professor Won Young Tak, MD, Ph.D., Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea and lead investigator in South Korea for the Company’s HEAT and OPTIMA studies. Professor Tak discussed data from Celsion’s latest HEAT Study post-hoc analysis, which suggests an overall survival benefit of over two years in the large subgroup of patients treated with ThermoDox plus optimized RFA (RFA > 45 minutes).

"Effect of Standardizing Radiofrequency Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox) on Overall Survival (OS) Among Patients with a Solitary 3 to 7 cm HCC Lesion: A HEAT Study Multivariate Analysis," by Dr. Shi-Ming Lin, MD, co-chair ACTA 2015, vice-chairman, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Taipei, Taiwan, and lead investigator in Taiwan for the Company’s HEAT and OPTIMA studies. Dr. Lin reviewed the extensive data from Celsion’s HEAT Study, including the results of multivariate analyses performed which clearly suggests that RFA heating or dwell time greater than 45 minutes was the only statistically significant variable that explained the significant improvement in overall survival (79 months in the optimized RFA plus ThermoDox subgroup versus 53.6 months in the optimized RFA only subgroup) in a large, well bounded subgroup of 285 patients (41% of the HEAT Study patients).

"Importance of Heating Time on the Local Drug Deposition During RFA in Combination with Lyso-Thermosensitive Liposomal Doxorubicin (LTLD) in a Porcine Model," by Nicholas Borys, MD, Celsion’s senior vice president and chief medical officer. Dr. Borys reviewed findings from a preclinical study demonstrating that in a porcine model, a direct correlation was observed between the duration of RFA heating, or dwell time, and the concentration of doxorubicin localized to the liver.
The presentation abstracts will be available on Celsion’s website at View Source

About Celsion’s Phase III OPTIMA Study

Celsion’s Phase III OPTIMA Study is a global pivotal, double-blind, placebo-controlled study evaluating ThermoDox, its proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with optimized radiofrequency ablation (RFA) in HCC. The study is expected to enroll up to 550 patients in over 75 clinical sites in the North America, Europe, China and Asia Pacific, and will evaluate ThermoDox in combination with optimized RFA, which will be standardized to a minimum of 45 minutes across all investigators and clinical sites for treating lesions three to seven centimeters, versus standardized RFA alone. The primary endpoint for the trial is overall survival, which is supported by post-hoc analysis of data from the Company’s 701 patient HEAT Study, where optimized RFA has demonstrated the potential to significantly improve survival when combined with ThermoDox. The statistical plan for the OPTIMA Study calls for two interim efficacy analyses by an independent Data Monitoring Committee (iDMC).

10-Q – Quarterly report [Sections 13 or 15(d)]

(Filing, 10-Q, Dara Biosciences, NOV 2, 2015, View Source [SID:1234507886])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Curis Announces Presentation of Preclinical Data From Small Molecule PD-L1/VISTA and IRAK4 Programs at the AACR-NCI-EORTC International Conference

On November 2, 2015 Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, reported that its collaborator, Aurigene Discovery Technologies Limited, will present data from two programs at the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) to be held from November 5 – 9, 2015, in Boston, MA (Press release, Curis, NOV 2, 2015, View Source [SID:1234507871]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Curis’ collaborator, Aurigene will present data from CA-170 (previously AUPM-170), a first-in-class oral, small molecule immune checkpoint antagonist targeting programmed death ligand-1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA) as well as from the interleukin-1 receptor association kinase4 (IRAK4) inhibitor program. Curis recently exercised options to license both these programs under a collaboration agreement with Aurigene established earlier this year.

Additional information on the presentations can be found below and abstracts can be accessed at www.aacr.org.

Poster Presentations

Date/Time: Friday, Nov. 6, 2015, 12:15 PM – 3:15 PM
Session Title: Immune Modulators
Presentation Title: First-in-class orally available immune checkpoint antagonists for cancer therapy
Location: Session A, Hall C-D
Abstract Number: A96

Date/Time: Sunday, Nov. 8, 2015, 12:30 PM – 3:30 PM
Session Title: Therapeutic Agents: Small Molecule Kinase Inhibitors
Presentation Title: Efficacy of novel IRAK4 inhibitors in ABC-DLBCL and AML models
Location: Session C, Hall C-D
Abstract Number: C191

10-Q – Quarterly report [Sections 13 or 15(d)]

(Filing, 10-Q, Rexahn, NOV 2, 2015, View Source [SID:1234507891])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Foundation Medicine Announces Roche Pharmaceuticals (Israel) Ltd. to Commence Commercial Activities in Support of its Molecular Information Products in Oncology

On November 2, 2015 Foundation Medicine, Inc. (NASDAQ:FMI) reported that F. Hoffmann La-Roche’s affiliate in Israel, Roche Pharmaceuticals (Israel) Ltd., will commence commercial activities in support of its suite of molecular information products (Press release, Foundation Medicine, NOV 2, 2015, View Source [SID:1234507872]). As part of the ex-US collaboration between Foundation Medicine and Roche, Roche Israel will act as the exclusive distributor of Foundation Medicine’s current products and services in Israel commencing as of October 24, 2015. The companies will also cooperate on the continued development of Foundation Medicine’s groundbreaking molecular information products to drive precision medicine and deliver improved clinical outcomes in cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted to initiate our ex-US collaboration with Roche Israel and bring a complete suite of molecular information products to the oncology community in Israel," stated David Daly, Chief Commercial Officer of Foundation Medicine. "Roche’s strong market presence will be a key differentiator for Foundation Medicine’s products, and ultimately will drive increased access to critical molecular information solutions that empower cancer care teams to make informed therapeutic treatment decisions and positively impact clinical outcomes for patients."

Roche Israel will commence commercial activities for Foundation Medicine’s end-to-end molecular information solutions, including FoundationOne for solid tumors, FoundationOne Heme for hematologic malignancies and sarcomas, and FoundationICE.

Avi Danziger, General Manager of Roche Israel stated: "The combination of Foundation Medicine’s molecular information suite of products and our expertise in oncology drug development supports our unified quest to tailor the best care and treatment for patients and take a leading position in doing now what patients need next."